Skip to content

Real-Time Assessment of Lung Structure and Function in Children and Young Adults With CF Using Electrical Impedance Tomography

Real-Time Assessment of Lung Structure and Function in Children and Young Adults With CF Using Electrical Impedance Tomography

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05455671
Enrollment
48
Registered
2022-07-13
Start date
2022-08-01
Completion date
2024-08-20
Last updated
2025-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis, Healthy

Brief summary

The purpose of this study is to determine the ability of electrical impedance tomography (EIT) to identify structural and functional physiological changes that occur with disease progression in cystic fibrosis patients. The investigators also aim to determine whether EIT can serve as an alternative for CT to identify regions of air trapping and consolidation, whether EIT can provide clinically useful information about response to treatment for an acute PE, and whether EIT can provide longitudinal information about structural changes in the lung.

Interventions

None listed

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Years to 21 Years
Healthy volunteers
Yes

Inclusion criteria

Cohort 1: * Age 3-21 years * Male or female * Healthy subjects with no known or suspected chronic or temporary lung disease Cohort 2: * Age 3-21 years * Male or female * CF as diagnosed based on sweat chloride value(\>60 mmol/L) or two known disease causing mutations Cohort 3: * Age 3-21 years * Male or female * CF as diagnosed based on sweat chloride value (\>60 mmol/L) or two known disease causing mutations * Experiencing a protocol defined pulmonary exacerbation and being started on oral or intravenous antibiotics

Exclusion criteria

* Unwilling/refusal to sign consent * Known congenital heart disease, arrhythmia, or history of heart failure * Wearing a pacemaker or a metallic surgical implant in the chest * History of infection with Burkholderia cepacia * Developmental delays that could result in an inability to complete study procedures

Design outcomes

Primary

MeasureTime frameDescription
Identification of air trapping and consolidation by EIT36 monthsThe detection task for identifying air trapping and consolidation is to determine by inspection regions of EIT VQ index significantly lower than the surrounding lung region, with actual numbers or relative differences to be determined as part of this study in the correlation analysis to CT scans.

Secondary

MeasureTime frameDescription
Determining utility of EIT information in response to treatment for a pulmonary exacerbation36 monthsIndividual outcome measures (CFCS, LCI , PFT, and EIT measures) will be evaluated using paired t-tests, and the corresponding t-statistics from each of the tests will be used as measures of effect size for comparison. In addition, all of the clinical outcomes can be compared statistically using a joint model approach (this is the same model that is referenced in Q3 below).
Determination of structural changes in the lung by EIT36 monthsThe EIT-derived global VQ indices, FEV1, FEV1/FVC, FVC, and extent of air trapping and consolidation will be studied longitudinally and compared to LCIs, PFTs, and CT scans when available to assess the ability of EIT to identify structural and reversible physiological changes that occur with disease progression. To estimate the change in the EIT measures of global VQ, air trapping and consolidation, and EIT-derived PFT outputs over time, a random coefficient model with an intercept and slope fit for each subject with at least two measurements over the 3 years will be used. A bivariate version of the random coefficients model will be fit to address whether the EIT outcome variable is associated with the spirometer PFT outputs, LCI, and CFCS while accounting for repeated measures.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026